Equity Method Investment	6 Months Ended
Jun. 30, 2026
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment	Equity Method Investment On September 16, 2025, the Company and Framatome formed Standard Nuclear x Framatome LLC (the “Joint Venture”), a Delaware limited liability company, with the purpose of establishing a facility on Framatome’s U.S. NRC -licensed site in Richland, Washington to manufacture and commercialize TRISO, Fully Ceramic Microencapsulated fuel (“FCM”), and other TRISO-based advanced fuel products. Pursuant to the Joint Venture’s LLC Operating Agreement, the Company agreed to contribute cash of $66,667 in exchange for a 66.667% membership interest and Framatome agreed to contribute cash of $33,333 in exchange for a 33.333% membership interest. In addition to the initial capital contributions, the Company will provide intellectual property licensing related to advanced fuel product technology and manufacturing know-how and to lease specialized fuel-manufacturing equipment to the Joint Venture. Framatome has agreed to provide access to its Richland site physical plant space and licensed nuclear infrastructure, to lease its specialty fuel building to the Joint Venture, and to license its manufacturing and operational expertise. As of June 30, 2026 and December 31, 2025, the carrying amount of the Company’s equity method investment in Standard Nuclear x Framatome LLC was $2.5 million and $1.1 million, respectively. During the three and six months ended June 30, 2026, the Company made $1.4 million of additional contributions to the Joint Venture. The Company’s share of the Joint Venture net gain or loss was not material. The Joint Venture remained in its pre-operational phase as of June 30, 2026, and had not commenced commercial production or generated revenue. The Company reevaluated its accounting conclusions related to the Joint Venture during the three months ended June 30, 2026, and determined that the Joint Venture continues to be accounted for under the equity method and continues to be a VIE for which the Company is not the primary beneficiary. As of June 30, 2026, the Company’s maximum exposure to loss was approximately $2.5 million, consisting of the carrying amount of its investment and any contractual funding commitments under the Joint Venture’s LLC Operating Agreement, and the Company has not provided any credit enhancements or other forms of financial support to the Joint Venture beyond those described above.

On September 16, 2025, the Company and Framatome formed Standard Nuclear x Framatome LLC (the “Joint Venture”), a Delaware limited liability company, with the purpose of establishing a facility on Framatome’s U.S. NRC -licensed site in Richland, Washington to manufacture and commercialize TRISO, Fully Ceramic Microencapsulated fuel (“FCM”), and other TRISO-based advanced fuel products.

Pursuant to the Joint Venture’s LLC Operating Agreement, the Company agreed to contribute cash of $66,667 in exchange for a 66.667% membership interest and Framatome agreed to contribute cash of $33,333 in exchange for a 33.333% membership interest. In addition to the initial capital contributions, the Company will provide intellectual property licensing related to advanced fuel product technology and manufacturing know-how and to lease specialized fuel-manufacturing equipment to the Joint Venture. Framatome has agreed to provide access to its Richland site physical plant space and licensed nuclear infrastructure, to lease its specialty fuel building to the Joint Venture, and to license its manufacturing and operational expertise.

As of June 30, 2026 and December 31, 2025, the carrying amount of the Company’s equity method investment in Standard Nuclear x Framatome LLC was $2.5 million and $1.1 million, respectively. During the three and six months ended June 30, 2026, the Company made $1.4 million of additional contributions to the Joint Venture. The Company’s share of the Joint Venture net gain or loss was not material. The Joint Venture remained in its pre-operational phase as of June 30, 2026, and had not commenced commercial production or generated revenue. The Company reevaluated its accounting conclusions related to the Joint Venture during the three months ended June 30, 2026, and determined that the Joint Venture continues to be accounted for under the equity method and continues to be a VIE for which the Company is not the primary beneficiary. As of June 30, 2026, the Company’s maximum exposure to loss was approximately $2.5 million, consisting of the carrying

amount of its investment and any contractual funding commitments under the Joint Venture’s LLC Operating Agreement, and the Company has not provided any credit enhancements or other forms of financial support to the Joint Venture beyond those described above.